论文部分内容阅读
目的通过对哮喘急性发作期患者治疗的观察,分析孟鲁司特对哮喘急性发作期患者外围血炎性因子的影响。方法选取医院收治的哮喘急性发作期患者70例,随机分为对照组和观察组,每组35例。对照组进行常规治疗,观察组在对照组治疗基础上加用孟鲁斯特钠片治疗,观察比较2组患者治疗前后外周血炎因子白介素-6以及干扰素-α水平。结果 2组在进行半个月治疗后,观察组治疗有效率为94.29%,高于对照组的77.14%(P<0.05)。治疗后,2组白介素-6水平较治疗前降低、干扰素-α含量较治疗前升高,且观察组降低、升高幅度大于对照组(P均<0.01)。结论孟鲁司特应用于哮喘急性发作期患者治疗中,具有明显的临床效果,且影响患者外周血炎性因子白介素-6、干扰素-α水平,值得临床推广应用。
Objective To investigate the effect of montelukast on peripheral blood inflammatory factors in patients with acute exacerbation of asthma by observing the treatment of patients with acute exacerbation of asthma. Methods Seventy patients with acute exacerbation of asthma admitted to hospital were randomly divided into control group and observation group with 35 cases in each group. The control group was treated routinely. The observation group was treated with montelukast sodium tablets on the basis of the control group. The levels of interleukin-6 and interferon-α in the two groups before and after treatment were observed and compared. Results After two weeks’ treatment, the effective rate of the observation group was 94.29%, higher than that of the control group (77.14%, P <0.05). After treatment, the levels of interleukin-6 in the two groups were lower than those before treatment. The levels of interferon-α in the two groups were higher than those before treatment, and the levels in the observation group were lower and higher than those in the control group (all P <0.01). Conclusion Montelukast can be used clinically in the treatment of patients with acute exacerbation of asthma. It has obvious clinical effect and affects the levels of interleukin-6 and interferon-α in peripheral blood in patients with asthma.